Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia (NCT05184335)
Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension
🩺 Plain-English Summary (8th-Grade Level)
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Who can join: Review the eligibility criteria below.
Location: Reviva site — Phoenix, Arizona
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Reviva site — Phoenix, Arizona
- Reviva site — Bentonville, Arkansas
- Reviva site — Little Rock, Arkansas
- Reviva site — Rogers, Arkansas
- Reviva site — Garden Grove, California
- Reviva site — Lemon Grove, California
- Reviva site — Riverside, California
- Reviva site — Hollywood, Florida
- Reviva site — Hollywood, Florida
- Reviva site — Miami Lakes, Florida
- Reviva site — Atlanta, Georgia
- Reviva site — Decatur, Georgia
- Reviva site — Chicago, Illinois
- Reviva site — Gaithersburg, Maryland
- Reviva site — Boston, Massachusetts
- Reviva site — Oklahoma City, Oklahoma
- Reviva site — Austin, Texas
- Reviva site — Richardson, Texas
📞 Contact the Study Coordinator
Phone: (408) 501-8881
Email: medicaldirector@revivapharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.